A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

NCT06176352 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization Secondary to Pathologic Myopia

Interventions

DRUG: Faricimab
DRUG: Ranibizumab
PROCEDURE: Sham Procedure

Sponsor

Hoffmann-La Roche